Literature DB >> 35030031

PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.

Margaret K Callahan1, Paul B Chapman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35030031      PMCID： PMC9061142          DOI： 10.1200/JCO.21.02801

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  13 in total

1.  Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Authors:  Taha Merghoub; Maria Jure-Kunkel; Jedd D Wolchok; Margaret K Callahan; Gregg Masters; Christine A Pratilas; Charlotte Ariyan; Jessica Katz; Shigehisa Kitano; Valerie Russell; Ruth Ann Gordon; Shachi Vyas; Jianda Yuan; Ashok Gupta; Jon M Wigginton; Neal Rosen
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

2.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

3.  Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Authors:  Paolo Antonio Ascierto; Pier Francesco Ferrucci; Antoni Ribas; Rosalie Fisher; Michele Del Vecchio; Victoria Atkinson; Henrik Schmidt; Jacob Schachter; Paola Queirolo; Georgina V Long; Anna Maria Di Giacomo; Inge Marie Svane; Michal Lotem; Gil Bar-Sela; Felix Couture; Bijoyesh Mookerjee; Razi Ghori; Nageatte Ibrahim; Blanca Homet Moreno
Journal:  Nat Med       Date:  2019-06-06       Impact factor: 53.440

4.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

5.  Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.

Authors:  Patrick A Ott; Trevor Henry; Sonja Jimenez Baranda; Davor Frleta; Olivier Manches; Dusan Bogunovic; Nina Bhardwaj
Journal:  Cancer Immunol Immunother       Date:  2013-01-10       Impact factor: 6.968

6.  Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.

Authors:  David R Minor; Igor Puzanov; Margaret K Callahan; Bruce A Hug; Axel Hoos
Journal:  Pigment Cell Melanoma Res       Date:  2015-06-23       Impact factor: 4.693

Review 7.  Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.

Authors:  Julianne D Twomey; Baolin Zhang
Journal:  AAPS J       Date:  2021-03-07       Impact factor: 4.009

8.  KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.

Authors:  Pier Francesco Ferrucci; Anna Maria Di Giacomo; Michele Del Vecchio; Victoria Atkinson; Henrik Schmidt; Jacob Schachter; Paola Queirolo; Georgina V Long; Rosalie Stephens; Inge Marie Svane; Michal Lotem; Mahmoud Abu-Amna; Eduard Gasal; Razi Ghori; Scott J Diede; Elizabeth S Croydon; Antoni Ribas; Paolo Antonio Ascierto
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

9.  BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.

Authors:  Stefanie Hoyer; Valentina Eberlein; Gerold Schuler; Carola Berking; Lucie Heinzerling; Niels Schaft; Jan Dörrie
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

10.  Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.

Authors:  Reinhard Dummer; Georgina V Long; Caroline Robert; Hussein A Tawbi; Keith T Flaherty; Paolo A Ascierto; Paul D Nathan; Piotr Rutkowski; Oleg Leonov; Caroline Dutriaux; Mario Mandalà; Paul Lorigan; Pier Francesco Ferrucci; Jean Jacques Grob; Nicolas Meyer; Helen Gogas; Daniil Stroyakovskiy; Ana Arance; Jan C Brase; Steven Green; Tomas Haas; Aisha Masood; Eduard Gasal; Antoni Ribas; Dirk Schadendorf
Journal:  J Clin Oncol       Date:  2022-01-14       Impact factor: 50.717
View more
  1 in total

Review 1.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.